Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
As of close of business last night, Arcus Biosciences Inc’s stock clocked out at $9.63, up 0.31% from its previous closing price of $9.60. In other words, the price has increased by $0.31 from its previous closing price. On the day, 0.64 million shares were traded.
Ratios:
To gain a deeper understanding of RCUS’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.37 and its Current Ratio is at 5.37. In the meantime, Its Debt-to-Equity ratio is 0.11 whereas as Long-Term Debt/Eq ratio is at 0.09.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, H.C. Wainwright on February 26, 2025, Upgraded its rating to Buy and sets its target price to $24 from $18 previously.
On October 21, 2024, H.C. Wainwright started tracking the stock assigning a Neutral rating and target price of $20. On October 08, 2024, Wells Fargo started tracking the stock assigning a Overweight rating and target price of $29.Wells Fargo initiated its Overweight rating on October 08, 2024, with a $29 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Feb 27 ’25 when KANEKO YASUNORI bought 20,000 shares for $10.06 per share. The transaction valued at 201,200 led to the insider holds 28,400 shares of the business.
ROSEN TERRY J bought 19,800 shares of RCUS for $201,465 on Feb 27 ’25. The Chief Executive Officer now owns 2,554,160 shares after completing the transaction at $10.18 per share. On Feb 18 ’25, another insider, GILEAD SCIENCES, INC., who serves as the 10% Owner of the company, bought 1,363,636 shares for $11.00 each. As a result, the insider paid 14,999,996 and bolstered with 31,424,760 shares of the company.
Stock Price History:
Over the past 52 weeks, RCUS has reached a high of $18.98, while it has fallen to a 52-week low of $6.50. The 50-Day Moving Average of the stock is 14.83%, while the 200-Day Moving Average is calculated to be -26.74%.
Shares Statistics:
A total of 105.90M shares are outstanding, with a floating share count of 63.89M. Insiders hold about 39.66% of the company’s shares, while institutions hold 62.43% stake in the company.
Earnings Estimates
The stock of Arcus Biosciences Inc (RCUS) is currently drawing attention from 3.0 analysts actively involved in the ongoing evaluation and rating process.The consensus estimate for the next quarter is -$1.18, with high estimates of -$1.13 and low estimates of -$1.24.
Analysts are recommending an EPS of between -$4.52 and -$5.04 for the fiscal current year, implying an average EPS of -$4.76. EPS for the following year is -$4.88, with 4.0 analysts recommending between -$3.93 and -$5.54.
Revenue Estimates
In the current quarter, 8 analysts expect revenue to total $32.86M. It ranges from a high estimate of $65M to a low estimate of $20M. As of the current estimate, Arcus Biosciences Inc’s year-ago sales were $39MFor the next quarter, 8 analysts are estimating revenue of $32.48M. There is a high estimate of $65M for the next quarter, whereas the lowest estimate is $20M.
A total of 10 analysts have provided revenue estimates for RCUS’s current fiscal year. The highest revenue estimate was $200M, while the lowest revenue estimate was $87.7M, resulting in an average revenue estimate of $127.51M. In the same quarter a year ago, actual revenue was $258MBased on 10 analysts’ estimates, the company’s revenue will be $168.66M in the next fiscal year. The high estimate is $283.67M and the low estimate is $44M.
